Perioperative low molecular weight heparin for infrageniculate bypass  by McMillan, William D. et al.
Perioperative low molecular weight 
heparin for infrageniculate bypass 
William D. McMil lan, MD,  Walter J. McCarthy,  MD,  Samuel J. Lin, BS, 
Jon S. Matsumura,  MD,  Wil l iam H.  Pearce, MD,  and 
James S. T. Yao, MD,  PhD,  Chicago, Ill. 
Purpose: Recent studies suggest that subcutaneous low molecular weight heparin 
(LMWH) is a safe, effective alternative to intravenous heparin (IVH) for deep venous 
thrombosis. LMWH may also be a safe, effective alternative to IVH when necessary for 
lower extremity bypass procedures performed with polytetrafluoroethylene (PTFE) 
grafts. The purpose of this study was to compare subcutaneous LMWH with IVH for 
perioperative anticoagulation i  patients who underwent infrageniculate bypass proce- 
dures with PTFE grafts. 
Methods: Of 361 lower extremity bypass operations performed at a single center over a 
32-month period, 76 were to the tibial or below-knee l vels using PTFE grafts for limb 
salvage. Seven patients were excluded because of absolute indications for perioperative 
IVH (ventricular thrombus in 1 patient, prosthetic valve in 2, cardiac dysrhythmia n 2, 
and documented hypercoagulable syndrome in 2), leaving 68 patients (35 women; mean 
age, 69.8 years) with 69 bypass procedures for study. Grafts completed in the past 16 
months were treated with LMWH (28 grafts; Oct. 1994 to Jan. 1996) and were 
compared with 41 consecutive control grafts from the previous 16-month interval (Apr. 
1993 to Oct. 1994) who received IVH. There were similar percentages of composite 
bypasses (IVH, 50%; LMWH, 46%), patients with tissue loss or gangrene (IVH, 56%; 
LMWH, 61%), and patients with prior ipsilateral bypass (IVH, 57%; LMWH, 56%) in 
each group. Age~ sex, and atherosclerotic risk factors were also similar between the two 
groups. 
Results: Morbidity rates (IVH, 19%; LMWH, 11%) and mortality rates (IVH, 2.5%; 
LMWH, 4%) were not significantly different. There were no significant differences in the 
number of grafts that failed before discharge (IVH, 1; LMWH, 0) or percentage of 
hemorrhagic complications (IVH, 15%; LMWH, 7%). The mean number of postoperative 
hospital days (IVH, 9.5; LMWH, 7.2; p < 0.009) and coagulation monitoring studies 
(IVH, 22; LMWH, 8.4; p < 0.0001) were significantly decreased in patients who were 
anticoagulated with LMWH. The mean number of days before conversion to oral 
anticoagulation (IVH, 7.3; LMWH, 8.0) did not differ significantly. 
Conclusions: When perioperative anticoagulation is deemed necessary, LMWH provides a
safe, effective alternative to IVH for infrageniculate PTFE bypass grafting procedures. 
LMWH may reduce the number of postoperative hospital days and coagulation studies by 
allowing discharge before therapeutic anticoagulation with warfarin. (J Vase Surg 1997; 
25:796-802.) 
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The predictable failure rates that are associated 
with infrainguinal bypass grafting procedures repre- 
sent a continuing challenge for practicing vascular 
surgeons. To date there is no consensus as to the 
optimal form of pharmacotherapy that should be 
used for the prevention of graft failure; however, a 
number of recent clinical trials have demonstrated 
the advantages of low molecular weight heparin 
(LMWH) for treatment of venous thromboembo- 
lism 1,2 and claudication, 3 as well as prophylaxis 
against late failure after femoropopliteal bypass graft- 
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ing procedures. 4 LMWHs, which are prepared by the 
&polymerization of standard heparin, have well- 
documented advantages over their parent com- 
pound, including better bioavailability, longer half- 
life, and a more predictable anticoagulant response 
when administered subcutaneously. 5-8 
The causes and general chronology ofinftaingui- 
nal graft failure are well documented. 9,1° In general, 
prosthetic infrageniculate bypass procedures per- 
formed for limb salvage have the highest rates of 
both early and late graft failure.i°,11Early failure rates 
for such bypass procedures are reported between 5% 
and 15%, 1°,12 much of which is attributable to tech- 
nical failure. Yet as many as 75% of infrageniculate 
polytetrafluoroethylene (PTFE) grafts may throm- 
bose after surgery solely because of poor runoff or 
thrombogenic luminal surfaces) 3 A number of 
agents are used in an attempt to reduce the incidence 
of postoperative thrombosis, including aspirin, di- 
pyridamole, dextran, warfarin, and intravenous hep- 
arin (IVH). Although Wt-I is generally thought o be 
the most effective in preventing postoperative throm- 
bosis, it is associated with higher rates of hemor- 
rhagic complication and greater associated costs than 
the other agents. Despite the paucity of clinical data 
supporting its effectiveness, heparin is often used 
empirically in an effort to improve the patency of 
prosthetic bypasses. The purpose of this study is to 
determine whether LMWH is as effective as IVH in 
preventing early postoperative graft thrombosis. 
We hypothesized that LMWH and WH would 
be equally effective in reducing the incidence of early 
postoperative graft failure in patients who undergo 
infrageniculate PTFE bypass procedures for limb sal- 
vage. Further, we hypothesized that anticoagulation 
with LMWH would result in shorter hospital stays 
and a reduction in the numbcr of coagulation moni- 
toring studies required by allowing for discharge 
before therapeutic anticoagulation with oral warfa- 
rin. 
MATERIAL AND METHODS 
Of 361 infrainguinal bypass procedures per- 
formed over a 32-month period at Northwestern 
Memorial Hospital, 76 were infrageniculate bypass 
procedures performed with PTFE grafts for limb 
salvage. Seven patients were excluded from the study 
because of an absolute indication for treatment with 
perioperative IVH, including ventricular thrombus 
in one patient, prosthetic cardiac valve in two, cardiac 
dysrhythmia in two, and documented hypercoagu- 
lable syndromes in two. The remaining 68 patients, 
who underwent 69 bypass procedures, comprised the 
Table I. Heparin dose titration nomogram 
APTTs Dose change U/hr Repeat 
<45 +200, rebolus 4 hr 
45 to 54 +100 4 hr 
55 to 75 0 daily 
76 to 90 -100 ,  stop 1 hr 4 hr 
>90 -200 ,  stop 1 hr 4 hr 
study group. All patients were given 5000 U of IVH 
in the operating room before the application of vas- 
cular clamps. No routine intraoperative monitoring 
of coagulation parameters was used. Twenty-eight 
bypass grafts completed between Oct. 2, 1994, and 
Feb. 1, 1996, were anticoagulated in the periopera- 
tive period with 60 mg of LMWH (Lovenox, Rone- 
Poulenc Rorer, Collegeville, Pa.) administered sub- 
cutaneously twice daily, with the initial dose given in 
the recovery room. Forty-one consecutive control 
grafts placed between June l, 1993, and Oct. 1, 
1994, were anticoagulated in the perioperative pe- 
riod with WH to maintain a target partial thrombo- 
plastin time of 55 to 75 seconds according to a 
previously published nomogram (Table I).14 In these 
patients the heparin drip was started in the recovery 
room at a rate of 15 units/kg/hour. The initial 
dose of warfarin was routinely given on the first 
day after surgery, and both groups were eventually 
converted to oral anticoagulation with warfarin 
when the international normalized ratio reached 
2.0 to 3.0. The medical records, including hospital 
stay and outpatient visits of every patient, were 
reviewed in accordance with the institutional re- 
view board of Northwestern University/McGaw 
Medical Center. End points of the study included 
conversion to oral anticoagulation or graft throm- 
bosis. A combination of Student's two-tailed t test 
and X 2 analysis was used for statistical comparison 
between the two groups. 
RESULTS 
Age, sex, and atherosclerotic risk factors were 
similar in the two groups (Table II) and did not differ 
from those reported elsewhere) °,n 
Every patient required bypass grafting for limb 
salvage (Table II). There were similar numbers of 
patients with ulcer, gangrene, and rest pain in each 
group. Likewise, the two groups had similar numbers 
of patients who had previously undergone ipsilateral 
lower extremity bypass procedures and similar num- 
bers of patients who required secondary procedures, 
such as toe or transmetatarsal amputations, during 
the same hospitalization. All patients had absent or 
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Table II. Patient characteristics and 
operative indications 
IVH LMWH 
& = 41) (n = 28) 
Mean age (yr) 70 69 
Male (%) " 52 48 
Smokers (%) 56 57 
Hypertension (%) 97 97 
Diabetes (%) 44 56 
Ulcer (%) 41 46 
Gangrene (%) 15 15 
Rest pain (%) 44 39 
Prior bypass (%) 57 56 
Secondary amputation (%) 21 19 
inadequate autogenous vein for the required bypass 
gra, ft. 
All bypass grafts in both groups used the femoral 
artery as their inflow source. Composite sequential 
bypass grafts comprised 39% of the IVH group and 
50% of the LMWH group (p = NS). The distal 
anastomotic sites were similar in the two groups and 
are listed in Table III. 
There were no significant differences in either 
morbidity (IVH, 19%; LMWH, 11%; p = NS) or 
mortality rates (1VH, 2.5%; LMWH, 4%; p = NS) for 
the two groups studied. One patient in the LMWH 
group died from hemorrhagic stroke on postopera- 
tive day 30, 3 days after conversion to warfarin and 3 
days after stopping the LMWH. One patient reated 
with WH died after rupture of a lmown thoracic 
aneurysm on postoperative day 14, 6 days after con- 
version to oral warfarin. 
There was no significant difference found in the 
rate of postoperative thrombosis, as only one patient 
in either group had graft failure while taldng heparin. 
This patient required thrombectomy of a composite 
sequential bypass graft on the third day after under- 
going surgery despite adequate anticoagulation with 
WH. The majority of complications that occurred in 
both groups resulted from hemorrhagic complica- 
tions. Two patients (7%) who were treated with 
LMWH had postoperative h matomas that required 
reoperation. Six patients, or 15% of those treated 
with IVH, had hemorrhagic complications; five had 
hematomas that required rainage and one had up- 
per gastrointestinal bleeding that required transfu- 
sion of three units of packed red blood cells. Al- 
though the number of hemorrhagic complications 
was not significantly different between groups (p = 
0.4), the higher number of such complications in the 
patients who received IVH accounted almost entirely 
for the observed increase in their morbidity rate 
(IVH, 19%; LMWH, 11%). There was only one su- 
perficial wound infection in either group. It occurred 
in a patient who had been given IVH, without post- 
operative hematoma, who was successfully treated 
with open drainage and administration f antibiotics. 
Patients who were treated with LMWH were 
hospitalized for significantly less time than those who 
were treated with IVH. The mean postoperative hos- 
pital stay in the LMWH group was 7.2 days (SD, 
_+3.7 days), whereas patients treated with IVH spent 
an average of 9.5 days (SD, _+3.3 days) in the hospi- 
tal (p < 0.008). Not surprisingly, the mean number 
of coagulation monitoring studies (i.e., prothrombin 
and partial thromboplastin times) required before 
conversion to warfarin in patients who were treated 
with LMWH was also significantly ess than that for 
patients who were treated with IVH (8.2 _+ 4.2 days 
vs 22.0 _+ 7.7 days; p < 0.0001). However, there was 
no significant difference in the mean number of days 
before conversion to oral anticoagulation between 
the two groups (IVH, 7.3 _+ 2.7 days; LMWH, 
8.0 -+ 3.1 days;p = 0.17). 
DISCUSSION 
Significant controversy till exists regarding both 
the optimal duration and type of postoperative anti- 
coagulation required after lower extremity bypass 
procedures. Numerous authors have advocated peri- 
operative and postoPerative anticoagulation for 
lower extremity bypass procedures with aspirin, 1Sq9 
perioperative dextran, ~° or WH, 2°,21 and long-term 
warfarin therapy 22-24 in an effort to improve graft 
patency. Conversely, others have shown no difference 
in either early or long-term patency rates in patients 
anticoagulated with heparin or warfarin. 2~,26 Among 
the studies that demonstrate b nefit, the greatest effect 
appears to be in those patients who undergo infra- 
geniculate PTFE bypass procedures3 ,4,1°,2s The single 
study that used LMWH for postoperative anticoagula- 
tion also demonstrated significant improvement in
long-term patency rates ofinfrainguinal grafts for limb 
salvage when compared with aspirin alone, but it of- 
fered no data on early thrombosis rates. 4Despite the 
fact that many chose to empirically treat with IVH in an 
effort o improve patency, to date there is no study that 
compares LMWH with IVH for prevention of early 
postoperative graft thrombosis. Our study compares 
perioperative LMWH with IVH in those patients 
who are at the highest risk for graft thrombosis; 
namely, patients who undergo infrageniculate pros- 
thetic bypass procedures for limb salvage. 
The results of this study demonstrate no signifi- 
cant difference in the rate of postoperative graft 
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Table III. Distal anastomosis 
Below-knee Posterior Anterior 
Graft type popl#eal tibial ~ tibial Peroneal Total 
PTFE LMWH (%) 8 (29%) 4 (14%) 1 (3.5%) 1 (3.5%) 14 (50%) 
PTFE IVH (%) 13 (32%) 7 (17%) 3 (8%) 2 (4%) 25 (61%) 
Composite LMWH (%) 2 (7%) 6 (22%) 1 (3.5%) 5 (17%) 14 (50%) 
Composite IVH (%) 0 (0%) 5 (22%) 1 (2%) l0 (25%) i6 (39%) 
Total LMWH (%) 10 (36%) 10 (36%) 2 (7%) " 6 (21%) 28 (100%) 
Total IVH (%) 13 (32%) 12 (29%) 4 (10%) 2 (29%) 41 (100%) 
thrombosis in patients who are anticoagulated with 
IVH and LMWH. Furthermore, anticoagulation 
with LMWH results in significant decreases in both 
length of postoperative hospitalization and the num- 
ber of anticoagulation studies required. Thus the 
main finding of this study is that anticoagulation with 
LMWI-I shifts a portion of the total cost of postoper- 
ative care to the outpatient setting and, in doing so, 
presumably lowers overall resource allocation. Un- 
fortunately, it has proved impossible to compare ac- 
tual postoperative hospital costs between the two 
groups because of recent changes in hospital com- 
puterized billing systems. Only objective data, in- 
cluding the postoperative length of stay and number 
of anticoagulation studies (both inpatient and outpa- 
tient), can be measured. However, some information 
is available as to the relative costs of LMWH and 
coagulation monitoring studies. The hospital cost for 
LMWH at our institution as of June 1, 1996, was 
$24.00 per 60 mg dose, whereas area pharmacies 
charge an average of $50.00 per 60 mg dose, making 
each day of anticoagulation with LMWH cost ap- 
proximately $100.00. The patient charge for a pro- 
thrombin time/partial thromboplastin time coagula- 
tion study at our institution is $90.50. Despite the 
relatively high price of LMWI-I, the savings accrued 
by avoiding an average of 13 (LMWH, 8.2; IVH, 
22) additional coagulation monitoring studies more 
than compensates for this cost. It appears then that 
the savings in laboratory testing alone, to say nothing 
of the potential reduction in postoperative hospital 
stays, may result in a significant decrease in resource 
allocation for patients treated with LMWH. 
There are several obvious criticisms of the appar- 
ent decrease in resource allocation for patients 
treated with LMWH. First, because the groups were 
not randomized, there was a potential bias toward 
shorter stay in patients who underwent bypass proce- 
dures more recently (i.e., patients treated with 
LMWH). Data were available for the average length 
of stay of patients who underwent infrainguinal by- 
pass procedures at Northwestern Memorial Hospital 
during the two intervals tudied. For fiscal year 1994 
the average postoperative l ngth of stay was 5.38 
days, whereas in fiscal year 1995 it was 4.85 days. 
Although the average postoperative l ngth of stay 
decreased by 0.53 days during the study, this did not 
account for the observed ecrease of 2.3 days in 
patients anticoagulated with LMWH. In fact, when 
0.53 days were added to every LMWH patient's 
postoperative length of stay, the difference in postop- 
erative length of stay remained significant (p - 
0.043). In almost every patient treated with IVH, 
the day of discharge was determined by when an 
adequate prothrombin time was achieved. 
Also of concern is the difference between the 
number of days required for anricoagulation (7.3 
days) and the average postoperative length of stay in 
the IVH group (9.5 days). This might suggest that 
factors other than the need for heparin before oral 
anticoagulation with warfarin accounted for the in- 
creased length of stay of the IVH group. However, 
careful analysis of the data provides aplausible xpla- 
nation. Both the standard eviation (_+3 days) and 
the range (3 to 18 days) in the time to oral anticoag- 
ulation were high, whether the patient was treated 
with IVH or LMWH. Although most patients were 
successfully converted to anticoagulation within 1 
week as expected, occasional patients, or "outliers," 
in both groups had difficulty with the conversion and 
therefore required heparin (either IVH or LMWH) 
for much longer intervals. For the patients in the 
IVH group, such difficulties translated irectly into 
increased hospital stays, whereas for patients in the 
LMWH group these difficulties were dealt with on an 
outpatient basis. Thus treatment with LMWH elim- 
inated the extra hospital days that resulted solely 
from the variable response to warfarin therapy (re- 
flected in the standard eviation, but not in the mean 
of the number of days before oral anticoagulation) 
and, in so doing, lowered the overall ength of stay. 
A final criticism concerns potential hidden costs 
and complications with home LMWH administra- 
tion. There was no significant difference in the per- 
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centage of patients who required home nursing (12% 
of IVH group, 16% of LMWH group) or in the 
number of patients readmitted within 30 days (1 
IVH, wound infection; 1 LMWH, amputation site 
breakdown). In addition, no patient reported hem- 
orrhagic complications while taking LMWH at 
home. Thus within the limits of anonrandomized, 
preliminary study, the decreases in postoperative 
hospital days and number of coagulation monitoring 
studies again appeared real. 
Although the rate of thrombosis was low in both 
groups, the incidence of hemorrhagic complications 
was high. The tradeoff between hematoma nd 
thrombosis i well recognized, and previous tudies 
that used postoperative heparin, 2°,21 dextran, 1° or 
LMWH4detail rates of hemorrhagic omplication 
ranging from 5% to 10%. The overall rate of 11% in 
the two groups in this study may have resulted from a 
combination of a significant percentage of patients 
who underwent reoperative procedures (56%) and an 
aggressive target range for partial thromboplastin 
times. Importantly, only one patient had a major 
hemorrhagic omplication. This involved a hemor- 
rhagic pontine stroke that occurred in a dialysis- 
dependent patient on postoperative day 30. LMWH 
had been discontinued 3 days before the event, and 
the patient had an international normalized ratio of 
2.3 on warfarin. It was surprising that the patients 
who were anticoagulated with IVH had a larger 
number of hemorrhagic omplications overall, as 
tighter control might have been expected in the IVH 
group. However, because differences in hemorrhagic 
complications between groups did not reach statisti- 
cal significance, no conclusions about he relative risk 
of such complications in patients who were anticoag- 
ulated with IVH or LMWH are possible. Finally, the 
11% rate of postoperative hematoma did not trans- 
late into high rates of postoperative infection or graft 
thrombosis in the two groups studied. 
The rate of postoperative thrombosis n our study 
was low, especially in light of the type of bypass 
procedure performed. The low rate of thrombosis 
may be partially explained by the study design. The 
end point of this study occurred when patients com- 
pleted treatment with heparin (either LMWH or 
BZH) and were taking oral warfarin at home. Patients 
who returned with failed grafts more than 30 days 
after surgery were not included as early failures. In 
fact, a review of patient records identified two such 
patients who had graft thrombosis hortly after .sur- 
gery. One patient initially treated with LMWH who 
had undergone a transmetatarsal amputation on the 
third day after surgery returned on postoperative day 
33 with a necrotic forefoot and a thrombosed graft 
that necessitated a below-knee amputation. A second 
patient initially treated with ~ underwent success- 
ful thrombectomy of a femoral-to-posterior tibia] 
PTFE bypass graft on postoperative day 37. Of note, 
none of the six patients who were excluded from the 
study had early graft thrombosis. Thus a more accu- 
rate representation f the early failure rate for the 
patients in this study is 4.4%, which is similar to those 
reported by others for composite sequential and 
PTFE tibia] bypass grafts. 12,27 
A significant question beyond the scope of the 
current study was whether the lower perioperative 
graft failure rates resulted in improvements in overall 
graft patency or limb salvage rates. Our aggressive 
perioperative anticoagulation may have only pro- 
longed graft thrombosis for a period of months with- 
out providing a lasting effect on graft survival. Al- 
though some previous tudies have shown improved 
long-term patency rates for this group of patients 
when anticoagulated with either warfarin 22-24 or 
LMWH, 4 significant controversy exists over optimal 
pharmacotherapy. The purpose of our study was only 
to compare LMWH with IVH, as many clinicians 
currently chose to empirically anticoagulate in an 
effort to prevent prosthetic graft failure despite a 
paucity of data regarding the overall efficacy of this 
strategy. Randomized studies that compare perioper- 
ative and postoperative r gimens of LMWH, subcu- 
taneous unfractionated heparin, warfarin, arid aspirin 
are needed. 
We conclude from this preliminary study that 
LMWH is as safe and effective as IVH for periopera- 
rive anticoagulation of infrageniculate bypass grafts 
using PTFE grafts. Within the limits of this prelimi- 
nary retrospective study, anticoagulation with 
LMWH appears to reduce the number of postopera- 
tive hospital days and coagulation studies required by 
allowing for discharge before therapeutic anticoagu- 
lation with warfarin. Prospective randomized trials 
that compare LMWH with IVH to assess both short- 
term and long-term graft patency are needed. 
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D ISCUSSION 
Dr. Thomas C. Bower (Rochester, Minn.). Perioper- 
ative anticoagulation is often used for patients who require 
infrageniculate bypass procedures for l imb-threatening 
ischemia who have poor run-offand otherwise lack suitable 
or adequate length of autogenous vein for the reconstruc- 
tion. The postoperative use of IVH, warfarin, a variety of 
antiplatelet agents, and low molecular weight dextran have 
all been studied in an effort to minimize or reduce the 
incidence of early graft failure or thrombosis. LMWH has a 
number of unique characteristics, asDr. McMillan nicely 
outlined for us, most of which are related to its unique 
pharmacokinetic properties. It can be given on a twice-per- 
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day dosage subcutaneously, and it does not require a large 
number of monitoring studies to monitor its coagulation 
effect. It is with this background that the authors in a 
preliminary report compared the role of LMWt-I with IVH 
in a cohort of patients who required infrageniculate by- 
pass procedures for limb salvage. All or part of the recon- 
structions were performed with PTFE grafts, two-thirds 
were performed to a tibial artery, and more than half the 
group were redo operations--certainly a laudable study 
group. 
Overall, I believe that their conclusions are valid and 
can be supported by their data, given the lack of random- 
ization in this study, that the analysis was performed on 
two nonconcurrent groups of patients, and, finally, that the 
end-point design allowed for only a very short period of 
observation: on average 7.3 days in the WH group and 8 
days in the LMWH group. The weal~esses of the study, 
however, have been nicely addressed by the authors both in 
the presentation and in the manuscript. LMWH may in- 
deed be a safe and effective alternative to IVH in selected 
cases, as there were no differences between the study 
groups with respect o death, graft occlusion, or hemor- 
rhagic complications. Intuitively, however, based on the 
pharmacoldnetics of LMWt-I, one would anticipate that 
fewer coagulation studies would be required, as was shown 
in this study. The reduction in hospital stay is suggested 
but perhaps not conclusively shown, as the authors have 
noted. 
I have several questions, most of which address the 
study design and protocol. When were the IVH, LMWH, 
and warfarin begun in the postoperative p riod? Was there 
any uniformity in the therapeutic interventions between 
the groups? Second, the dosage of LMWH that you used 
was 60 mg twice daily administered subcutaneously. Was 
this an arbitrary dose, or did you consider using a more 
standard ose, which would be 1 mg/kg twice daily? If it 
was an arbitrary dose, did any patient have antifactor Xa 
levels drawn to show that at least here was some adequate 
level of anticoagulation? Third, what percent of your pa- 
tients achieved the target activated partial thromboplastin 
time, and were the hemorrhagic omplications that ac- 
counted for the increased length of stay in the patient 
population related to an overshoot of the target level? 
Fourth, what were your criteria for hospital dismissal, and 
how has that affected length of stay? Finally, how have 
these data affected your current practice in the manage- 
ment of these patients? 
I believe that the Northwestern University group has 
laid the foundation for further research in this area. This 
was a very nice presentation a d a well-written manuscript, 
and I would like to thank the Society for the privilege of 
commenting on this paper. 
Dr. Will iam D. McMillan. First, we recognize and 
agree that the study was not randomized and therefore has 
some inherent weal~nesses. In our opinion, this was a 
preliminary study that was designed to justify the use of a 
prospective study at a later date. 
With regard to when the heparin was started, our 
patients are treated with a 5000 U intraoperative bolus of 
IVH. In the recovery room, patients are either given 15 
U /kg /hr  of IVH with no bolus or 60 mg of subcutaneous 
Lovenox. 
The dosage of LMWH was chosen on the basis of our 
understanding of limited studies of Lovenox at the time we 
began using it. We decided on 60 mg because it was more 
than the prophylactic dose of 30 mg. Since we began using 
Lovenox, several large studies have proposed that 1 mg/kg 
dose is an appropriate dose, and we have incorporated this 
into our practice lately. No patient in our study had a factor 
Xa level measured when they were taking Lovenox. 
To answer the question about what percentage of 
patients overshot, the overall number in either group who 
were supratherapeutic is unknown, but suffice it to say that 
many patients in the IVH group had a partial thromboplas- 
tin time of greater than 100 seconds at some point. This, I 
think, may have been picked up by the fact that we ob- 
tained coagulation monitoring studies quite often, on the 
average of every 6 hours. In the Lovenox group we were 
not able to determine whether patients had supratherapeu- 
tic partial thromboplastin times or whether that related to 
hematoma because we were not measuring their partial 
thromboplastin time routinely. Of all patients with hema- 
toma, only two of the seven were identified to have had a 
partial thromboplastin time greater than 100 seconds in 
the previous 12 hours. 
With regards to the question about hospital discharge, 
our criteria for discharge included that the patient was able 
to ambulate safely, that their wounds were without drain- 
age or erythema, and that their pain was controlled with 
oral medication. Finally, the international normalized ratio 
of the patients in the IVt-I group had to be between 2.0 to 
3.0, indicating that adequate dose of warfarin with ade- 
quate levels had been achieved. 
